Small Pharmacies Accuse FDA of Favoring Big Pharma over Consumers
BREITBART
The FDA is under fire over a recent decision to declare an end to the shortage of semaglutide and tirzepatide, the active ingredients in popular weight-loss and diabetes medications collectively known as GLP-1 drugs. The decision hurts small pharmacies while helping pharma giants like Novo Nordisk.
The explosion in popularity of GLP-1 drugs led the FDA to announce a shortage in 2022, allowing compounding pharmacies to and sell the drugs at much lower cost to consumers than branded versions such as Ozempic, the semaglutide-based GLP-1 produced by Danish company Novo Nordisk.
In October, under the Biden administration, the FDA attempted to rescind the shortage, but was blocked from doing so after a court challenge by the Outsourcing Facilities Association (OFA), a trade group that represents compounding pharmacies.
In a decision last week, a federal judge sided with the FDA, meaning smaller pharmacies must now immediately stop making compounded versions of tirzepatide, the active ingredient in GLP-1 drugs including Zepbound and Mounjaro. A separate decision on semaglutide, the active ingredient in Ozempic, is pending.
On the tirzepatide decision, OFA Chair Lee Rosebush said the group “is considering all of its options regarding the judgment, including an appeal.”
Should smaller pharmacies be forced out of the market, Big Pharma companies like Novo Nordisk will once again have a monopoly on production and supply. This is likely to raise costs for consumers, since compounded versions of the drugs tend to be sold at vastly lower prices.
This is particularly important for uninsured patients, or patients whose insurance does not cover the weight-loss drugs.
In its lawsuit against the FDA, the OFA accused the agency of “abruptly depriving patients of much needed treatment and artificially raising drug prices.”
The looming threat of an end to the official semaglutide shortage has already had major effects on telehealth companies providing compounded versions of the medication. For example, Hims & Hers Health Inc announced it would end the sale of compounded semaglutide products, causing a 27 percent drop in the company’s stock value.
Big pharma companies allege that their FDA-approved branded products are safer and more reliable than compounded alternatives. For example, a spokesperson for Eli Lilly said the recent court ruling was a welcome end to “risky, unapproved knockoffs” of Zepbound and Mounjaro, its branded tirzepatide injections.
Read more at the Hill here.
Header featured image (Edited) credit: PHOTO: JOE RAEDLE/GETTY IMAGES. Emphasis added by (TLB)
••••
••••
Stay tuned tuned…
••••
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
••••
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
••••
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
••••
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Leave a Reply